Clergue-Duval Virgile, Nicolas-Sacy Louise, Karsinti Emily, Zerdazi El-Hadi, Laplanche Jean-Louis, Brousse Georges, Marees Andries T, Derks Eske M, Henry Patrick, Bellivier Frank, Vorspan Florence, Bloch Vanessa
APHP, Département de Psychiatrie et de Médecine Addictologique, Site Lariboisière Fernand-Widal, Groupe hospitalier universitaire APHP Nord - Université de Paris, Paris, France.
Inserm UMRS-1144 Optimisation Thérapeutique en Neuropsychopharmacologie, Université de Paris, Paris, France.
Front Psychiatry. 2021 Jul 21;12:704276. doi: 10.3389/fpsyt.2021.704276. eCollection 2021.
Cocaine users often present with repetitive events of cocaine-associated chest pain (CACP), clinically resembling acute coronary syndromes. The aim of the study is to describe the specific risk factors for CACP. Cocaine users ( = 316) were recruited for a multicenter cross-sectional study. Lifetime CACP history, sociodemographic factors, and lifetime use of cocaine and other substances were assessed. Thirty single nucleotide polymorphisms (SNPs) of NOS3, ROCK2, EDN1, , and genes, suggested by the literature on coronary spasms, were selected. The associations with CACP history were tested using the chi-square test, Student's -test and logistic regression. Among the 316 subjects [78.5% men, mean age 37.5 years, (standard-deviation ±8.7)], 190 (60.1%) were daily cocaine users and 103 (32.6%) reported a lifetime CACP history. Among those with a lifetime CACP history, the median was 10 events per individual. In multivariate analysis, lifetime CACP history was associated with daily cocaine use [odds-ratio (OR) 3.24; 95% confidence intervals (1.29-9.33)], rapid route of cocaine use [OR 2.33 (1.20-4.64) vs. intranasal use], and lifetime amphetamine use [daily amphetamine use: OR 2.80 (1.25-6.32) and non-daily amphetamine use: OR 2.14 (1.15-4.04) vs. never used]. Patients with lifetime opioid maintenance treatment (OMT) reported significantly less lifetime CACP history [OR 0.35 (0.16-0.76)]. None of the selected SNPs was associated with CACP history after multiple testing corrections. Clinical variables describing the intensity of stimulant use were positively associated with lifetime CACP history, while OMT was negatively associated with it. Specific harm reduction strategies can target these risk factors.
可卡因使用者经常出现与可卡因相关的胸痛(CACP)反复发作的情况,临床上类似于急性冠状动脉综合征。本研究的目的是描述CACP的特定风险因素。招募了316名可卡因使用者进行一项多中心横断面研究。评估了终生CACP病史、社会人口学因素以及可卡因和其他物质的终生使用情况。根据关于冠状动脉痉挛的文献,选择了NOS3、ROCK2、EDN1等基因的30个单核苷酸多态性(SNP)。使用卡方检验、学生t检验和逻辑回归来检验与CACP病史的关联。在316名受试者中[78.5%为男性,平均年龄37.5岁,(标准差±8.7)],190人(60.1%)为每日可卡因使用者,103人(32.6%)报告有终生CACP病史。在有终生CACP病史的人中,每人发作次数的中位数为10次。在多变量分析中,终生CACP病史与每日使用可卡因[比值比(OR)3.24;95%置信区间(1.29 - 9.33)]、可卡因的快速使用途径[OR 2.33(1.20 - 4.64),与鼻内使用相比]以及终生使用苯丙胺[每日使用苯丙胺:OR 2.80(1.25 - 6.32),非每日使用苯丙胺:OR 2.14(1.15 - 4.04),与从未使用相比]相关。有终生阿片类药物维持治疗(OMT)的患者报告的终生CACP病史明显较少[OR 0.35(0.16 - 0.76)]。在多次检验校正后,所选的SNP均与CACP病史无关。描述兴奋剂使用强度的临床变量与终生CACP病史呈正相关,而OMT与之呈负相关。特定的减少伤害策略可以针对这些风险因素。